Shanghai Junshi Biosciences Co., Ltd. voluntarily discloses the progress of the share purchase by one of its controlling shareholders, actual controllers, and chairman of the board

Log in to Sina Finance App and search for [Disclosure] to see more evaluation levels

Securities Code: 688180 Stock Abbreviation: Junshi Biosciences Announcement No.: Lin 2026-020

Shanghai Junshi Biosciences Medical Technology Co., Ltd.

Voluntary Disclosure on the Progress of Share Increase by One of the Controlling Shareholders and Actual Controllers, and Chairman

The company’s board of directors, all directors, and relevant shareholders guarantee that the content of this announcement contains no false records, misleading statements, or major omissions, and bear legal responsibility for its truthfulness, accuracy, and completeness.

Key Highlights:

● Shanghai Junshi Biosciences Medical Technology Co., Ltd. (hereinafter referred to as “the Company”)'s controlling shareholder, one of the actual controllers, and Chairman Mr. Xiong Jun plans to increase his holdings of the Company’s A-shares and H-shares within 12 months starting from April 12, 2025, through methods permitted by the Shanghai Stock Exchange trading system and the Hong Kong Stock Exchange (including but not limited to centralized bidding and block trades), with a total increase of no less than RMB 100 million, of which at least RMB 50 million will be in A-shares.

● As of the disclosure date of this announcement, Mr. Xiong Jun has cumulatively increased his holdings of the Company’s A-shares by 365,382 shares through centralized bidding on the Shanghai Stock Exchange, accounting for approximately 0.04% of the company’s total share capital, with a total transaction amount of RMB 12,206,579.60. The plan for this share increase has not yet been completed, and Mr. Xiong will continue to increase his holdings of the company’s shares as appropriate during the implementation period of the plan.

● There are risks that the implementation of this share increase plan may not meet expectations due to changes in the capital market or other unpredictable risk factors.

1. Basic Information of the Share Increase Subject

■

Note 1: Before implementing the plan, Mr. Xiong directly held 87,856,618 shares of the company (including 87,854,018 A-shares and 2,600 H-shares, with the H-shares held in the name of HKSCC NOMINEES LIMITED as nominee);

Note 2: The shareholding ratio before the plan is based on the company’s current total share capital of 1,026,689,871 shares.

The above share increase subject has common action persons:

■

Note: The shareholding ratio is calculated based on the company’s total share capital of 1,026,689,871 shares.

2. Progress of the Share Increase Plan

■

As of the disclosure date of this announcement, the company’s controlling shareholder, actual controllers Mr. Xiong Jun and Mr. Xiong Fengxiang, along with their concerted action persons, hold a total of 184,348,568 shares, accounting for 17.96% of the company’s total share capital.

The plan for this share increase has not yet been completed. Based on confidence in the company’s operational development and recognition of its growth value, Mr. Xiong will continue to increase his holdings of the company’s shares as appropriate during the implementation period of the plan.

3. Risks Related to the Implementation of the Share Increase Plan

(1) There is a risk that the plan may not achieve expected results due to changes in the capital market or other unpredictable risk factors.

(2) Whether this plan will lead to changes in the company’s controlling shareholder and actual controllers: □Yes √No

(3) More than half of the original planned increase period has passed, but the actual increase amount has not reached half or the lower limit of 50% of the interval: √Yes □No

(4) Whether the share increase subject has terminated the plan early: □Yes √No

(5) Other risk warnings: There is a risk that the plan may not be implemented or may not meet expectations due to changes in the securities market or policy factors. The company will fulfill its information disclosure obligations in a timely manner if relevant risks occur during the implementation process.

4. Other Remarks

(1) During the implementation of this share increase plan, the share increase subject will comply with relevant regulations of the China Securities Regulatory Commission, Shanghai Stock Exchange, and Hong Kong Stock Exchange regarding changes in listed company interests and sensitive periods for stock trading.

(2) The company will continuously monitor the progress of this plan and fulfill its information disclosure obligations in accordance with the “Company Law of the People’s Republic of China,” “Securities Law of the People’s Republic of China,” “Administrative Measures for the Takeover of Listed Companies,” “Shanghai Stock Exchange STAR Market Listing Rules,” “Hong Kong Stock Exchange Listing Rules,” and other relevant laws, administrative regulations, departmental rules, and normative documents.

(3) The implementation of this plan will not affect the company’s share distribution to meet listing conditions, nor will it cause changes in the company’s controlling shareholder and actual controllers.

This announcement is hereby made.

Shanghai Junshi Biosciences Medical Technology Co., Ltd.

Board of Directors

March 17, 2026